Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA in Combination With Chemotherapy in Advanced or Metastatic Solid Tumors
NCT02495896Phase 1Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Sep 2015
- Primary completion
- Apr 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of sephb4-hsa in pancreatic cancer (PC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 2 more (3 arms), sponsored by University of Southern California. Primary endpoints: Duration of overall response or SD up to 2 years, Incidence of toxicities up to 2 years and 3 more. Started Sep 2015; status: active, not recruiting.
02
Drugs
sephb4-hsa
03
Conditions
pancreatic cancer (PC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT02495896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495896.